EU/3/24/2923 - orphan designation for treatment of small cell lung cancer

7-Ethyl-10-hydroxycamptothecin, Irinotecan hydrochloride trihydrate
OrphanHuman

Overview

This medicine was designated as an orphan medicine for treatment of small cell lung cancer on 24 May 2024.

This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.

Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:  

Key facts

Active substance
7-Ethyl-10-hydroxycamptothecin, Irinotecan hydrochloride trihydrate
Intended use
Treatment of small cell lung cancer
Orphan designation status
Positive
EU designation number
EU/3/24/2923
Date of designation
Sponsor

3R Pharma Consulting GmbH
 

 

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Share this page